94 related articles for article (PubMed ID: 22883281)
1. Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.
Yılmaz Ü; Gücüyener K; Atak A; Aral A; Gürkaş E; Demir E; Serdaroğlu A
Pediatr Neurol; 2012 Sep; 47(3):171-6. PubMed ID: 22883281
[TBL] [Abstract][Full Text] [Related]
2. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X
Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
4. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E
J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.
Sellner J; Greeve I; Leib SL; Mattle HP
Arch Neurol; 2008 May; 65(5):672-4. PubMed ID: 18474748
[No Abstract] [Full Text] [Related]
7. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
8. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F; Elias B; Hartung HP; Kieseier BC
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
Galboiz Y; Shapiro S; Lahat N; Rawashdeh H; Miller A
Ann Neurol; 2001 Oct; 50(4):443-51. PubMed ID: 11601495
[TBL] [Abstract][Full Text] [Related]
11. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis.
Waubant E; Gee L; Miller K; Stabler G; Goodkin D
J Interferon Cytokine Res; 2001 Mar; 21(3):181-5. PubMed ID: 11331041
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F
J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
[TBL] [Abstract][Full Text] [Related]
13. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-7, matrix metalloproteinase-9, and disease activity in pediatric multiple sclerosis.
Yılmaz U; Gücüyener K; Gürkaş E; Demir E; Serdaroğlu A; Atak A; Aral A; Oner YA
Pediatr Neurol; 2013 Mar; 48(3):255-6. PubMed ID: 23419482
[No Abstract] [Full Text] [Related]
15. Comment on "matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis".
Zahednasab H; Balood M; Mesbah-Namin SA
Pediatr Neurol; 2013 Mar; 48(3):255. PubMed ID: 23419481
[No Abstract] [Full Text] [Related]
16. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in multiple sclerosis.
Gerlach RF; Tanus-Santos JE
Clin Neurol Neurosurg; 2006 Sep; 108(6):617-8; author reply 618. PubMed ID: 16413675
[No Abstract] [Full Text] [Related]
17. Proteolytic balance in patients with multiple sclerosis during interferon treatment.
Giannelli G; De Marzo A; Scagnolari C; Bergamini C; Fransvea E; Bagnato F; Bellomi F; Millefiorini E; Gasperini C; Antonaci S; Antonelli G
J Interferon Cytokine Res; 2002 Jun; 22(6):689-92. PubMed ID: 12162880
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
20. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
